Overview of hybrid closed loops - key concepts, options available and choosing the right system
Wednesday 21st July 2021, 17.00 - 18.30
The DTN-UK are delighted to launch a three-part webinar series on hybrid-closed loop systems.
Developed by GIRFT, this guide is to support the health and wellbeing of people with diabetes as they await surgury.
Diabetes UK have announced the launch of their new campaign Diabetes is Serious, which aims to highlight the learnings and insights from their Diabetes Can't Wait report about the experiences people with diabetes have had during the coronavirus pandemic.
A new 12 week NHS Digital Weight Management Programme (DWMP) has formally launched today for people living with obesity and diabetes or hypertension. Referrals are via general practice. The slide below explains how this fits into existing weight management services.
More details can be found at NHS England » Enhanced service specification: Weight management 2021/22
Users of the FreeStyle Libre system in the UK show improvements in glycaemic control and awareness of hypoglycaemia which are associated with improvement in diabetes-related distress, according to a new study1 by Dr Harshal Deshmukh, from Hull University Teaching Hospitals NHS Trust, and colleagues.
Today at ADA 2021, ABCD is pleased to announce the launch of the ABCD nationwide oral semaglutide audit. As you will know, the clinical trials with semaglutide suggest that it may be more effective than the other GLP-1 receptor agonists. Results from the ABCD semaglutide audit, presented this weekend at ADA 2021, have demonstrated significant reductions in HbA1c and weight following commencement of semaglutide in a real-world cohort that was heavier with higher baseline HbA1c levels than those in clinical trials.
King's College London are seeking applications for the prestigious RD Lawrence Chair. For further information please see the detailed advertisement.
The ABCD Empagliflozin audit has provided valuable insights into empagliflozin use in UK based real-world practice. Additionally, data from the other SGLT2 audit programmes has demonstrated reductions in ALT as a marker of liver inflammation following commencement, with reductions much greater in those with elevated levels at baseline.
